InoKare is developing small molecules for obesity and other metabolic diseases. InoKare’s lead asset, IK-101, targets a unique MOA with pleiotropic downstream impacts.
Close Search Window
InoKare is developing small molecules for obesity and other metabolic diseases. InoKare’s lead asset, IK-101, targets a unique MOA with pleiotropic downstream impacts.